Editas Medicine Inc.

7.05-0.2800-3.82%Vol 1.42M1Y Perf -43.40%
Oct 4th, 2023 16:00 DELAYED
BID6.97 ASK7.36
Open7.32 Previous Close7.33
Pre-Market- After-Market7.35
 - -  0.30 4.26%
Target Price
16.64 
Analyst Rating
Moderate Buy 2.18
Potential %
136.03 
Finscreener Ranking
★★★+     50.74
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     49.94
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     50.80
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.11 
Earnings Rating
Strong Buy
Market Cap575.51M 
Earnings Date
1st Nov 2023
Alpha-0.01 Standard Deviation0.26
Beta1.79 

Today's Price Range

6.997.32

52W Range

6.3314.23

5 Year PE Ratio Range

-12.90-10.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.88%
1 Month
-20.16%
3 Months
-14.86%
6 Months
2.92%
1 Year
-43.40%
3 Years
-75.81%
5 Years
-75.32%
10 Years
-

TickerPriceChg.Chg.%
EDIT7.05-0.2800-3.82
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
9.90
10.10
0.02
0.05
219.50
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-795.90
-771.50
-466.50
-87.89
RevenueValueIndustryS&P 500US Markets
13.18M
0.19
4.85
34.13
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.76-0.5626.32
Q01 2023-0.79-0.7110.13
Q04 2022-0.84-0.88-4.76
Q03 2022-0.87-0.816.90
Q02 2022-0.84-0.787.14
Q01 2022-0.81-0.748.64
Q04 2021-0.78-0.6121.79
Q03 2021-0.86-0.5733.72
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.6414.67Positive
12/2023 QR-0.694.17Positive
12/2023 FY-2.5515.56Positive
12/2024 FY-2.6813.27Positive
Next Report Date1st Nov 2023
Estimated EPS Next Report-0.64
Estimates Count10
EPS Growth Next 5 Years %13.80
Volume Overview
Volume1.42M
Shares Outstanding81.63K
Shares Float79.84M
Trades Count14.69K
Dollar Volume10.10M
Avg. Volume1.94M
Avg. Weekly Volume2.67M
Avg. Monthly Volume1.70M
Avg. Quarterly Volume1.44M

Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 7.05 per share at the end of the most recent trading day (a -3.82% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 575.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.

The one-year performance of Editas Medicine Inc. stock is -43.4%, while year-to-date (YTD) performance is -20.52%. EDIT stock has a five-year performance of -75.32%. Its 52-week range is between 6.33 and 14.23, which gives EDIT stock a 52-week price range ratio of 9.11%

Editas Medicine Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.49, a price-to-sale (PS) ratio of 42.90, a price to cashflow ratio of 616.40, a PEG ratio of -0.22, a ROA of -35.33%, a ROC of -39.15% and a ROE of -44.12%. The company’s profit margin is -87.89%, its EBITDA margin is -771.50%, and its revenue ttm is $13.18 Million , which makes it $0.19 revenue per share.

Of the last four earnings reports from Editas Medicine Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.64 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 01st Nov 2023.

The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.18), with a target price of $16.64, which is +136.03% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Editas Medicine Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.94, ATR14 : 0.48, CCI20 : -87.57, Chaikin Money Flow : -0.27, MACD : -0.41, Money Flow Index : 24.08, ROC : -12.63, RSI : 39.70, STOCH (14,3) : 28.37, STOCH RSI : 0.78, UO : 37.01, Williams %R : -71.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Bruce Eaton (Sold 4 536 shares of value $45 158 ), Eaton Bruce (Sold 4 765 shares of value $46 500 ), Mark S. Shearman (Sold 2 790 shares of value $26 966 ), Mei Baisong (Sold 4 317 shares of value $37 990 ), Michelle Robertson (Sold 6 416 shares of value $59 342 ), Robertson Michelle (Sold 7 172 shares of value $66 754 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (46.67 %)
6 (40.00 %)
6 (37.50 %)
Moderate Buy
1 (6.67 %)
1 (6.67 %)
1 (6.25 %)
Hold
5 (33.33 %)
6 (40.00 %)
7 (43.75 %)
Moderate Sell
1 (6.67 %)
1 (6.67 %)
1 (6.25 %)
Strong Sell
1 (6.67 %)
1 (6.67 %)
1 (6.25 %)
Summary RatingModerate Buy
2.18
Moderate Buy
2.31
Moderate Buy
2.36

Editas Medicine Inc.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.

CEO: Cynthia Collins

Telephone: +1 617 401-9000

Address: 11 Hurley Street, Cambridge 02141, MA, US

Number of employees: 235

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

 

TipRanks News for EDIT

Thu, 28 Sep 2023 20:46 GMT Editas Medicine upgraded to Buy from Hold at Stifel

- TipRanks. All rights reserved.

News

Stocktwits